AI Article Synopsis

  • The Christie NHS Foundation Trust launched an electronic patient-reported outcome measures (ePROMs) service for lung cancer patients in January 2019, enabling them to report symptoms and quality of life (QoL) online.
  • Over 1,400 patients participated, with results showing significant differences in symptoms related to ECOG performance status and comorbidity scores, but no notable differences among age groups.
  • Patients receiving palliative treatment reported improvements in cough and hemoptysis, though mobility declined; those undergoing radical thoracic radiotherapy experienced better hemoptysis but worse pain and fatigue.

Article Abstract

Purpose: The Christie NHS Foundation Trust launched their electronic patient-reported outcome measures (ePROMs) service in January 2019 in the routine clinical setting. The lung cancer questionnaires consist of 14 symptom items, adapted from the Common Terminology Criteria for Adverse Events (version 5.0) and the EuroQol EQ-5D-5L quality-of-life (QoL) tool. Patients with lung cancer are invited to complete questionnaires assessing their symptoms and QoL using an online platform.

Methods: The ePROM responses and clinical, pathologic, and treatment data for patients who completed the questionnaires between January 2019 and December 2020 were extracted from electronic medical records. The symptom and QoL scores of patients who completed baseline pretreatment ePROMs and also those who completed ePROMs pre- and postpalliative lung systemic anticancer therapy (SACT) or radical thoracic radiotherapy were evaluated. Pretreatment questionnaires were analyzed according to age, Eastern Cooperative Oncology Group performance status (ECOG PS), and Adult Comorbidity Evaluation-27 (ACE-27) comorbidity score.

Results: One thousand four hundred eighty patients with lung cancer were included. There were no statistically significant differences in symptoms and QoL scores between age groups. Cough ( = .006) and EQ-5D-5L mobility scores ( = .006) were significantly worse for patients with an ECOG PS of 0-1. Dyspnea ( = .035), hemoptysis ( = .023), nausea ( = .041), mobility ( = .004), and self-care ( = .0420) were significantly worse for those with higher ACE-27 scores (2-3 0-1). Palliative SACT was associated with a significant improvement in cough ( < .001) and hemoptysis ( = .025), but significantly negatively affected mobility ( = .013). Patients receiving radical thoracic radiotherapy reported a significant improvement in hemoptysis ( = .042) but worse pain ( = .002) and fatigue ( = .01). Other changes in symptom and QoL scores were not significant.

Conclusion: The symptoms and QoL reported at baseline and before and after both palliative SACT and radical thoracic radiotherapy are clinically relevant and meaningful. We have demonstrated that routine implementation of ePROMs into clinical practice is feasible and can inform clinical practice and future research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281443PMC
http://dx.doi.org/10.1200/CCI.22.00150DOI Listing

Publication Analysis

Top Keywords

lung cancer
16
patients lung
12
symptoms qol
12
qol scores
12
radical thoracic
12
thoracic radiotherapy
12
electronic patient-reported
8
patient-reported outcome
8
outcome measures
8
january 2019
8

Similar Publications

Background: The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) for adults who meet specific age and smoking history criteria.

View Article and Find Full Text PDF

Objective: To investigate the effect of Brucea javanica Oil combined with chemotherapy on serum cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), immune mechanism, and prognosis in patients with lung cancer and provide a reference for its clinical diagnosis and treatment.

Methods: This study involved 112 lung cancer patients from June 2019 to January 2022 at Shanghai Guanghua Hospital. They were randomly divided into two groups: control (chemotherapy only) and observation (chemotherapy + Brucea javanica oil emulsion).

View Article and Find Full Text PDF

Brain metastasis (BM) is a poor prognostic factor in cancer patients. Despite showing efficacy in many extracranial tumors, immunotherapy with anti-PD-1 monoclonal antibody (mAb) or anti-CTLA-4 mAb appears to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti-PD-1 and anti-CTLA-4 mAbs has a potent antitumor effect on BM, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies.

View Article and Find Full Text PDF

Pulmonary metastasis represents one of the most prevalent forms of metastasis in advanced melanoma, with mortality rates reaching 70%. Current treatments including chemotherapy, targeted therapy, and immunotherapy frequently exhibit limited efficacy or present high costs. To address these clinical needs, this study presents a biomimetic drug delivery system (Ce6-pTP-CsA) utilizing cryoshocked adipocytes (CsA) encapsulating the prodrug triptolide palmitate (pTP) and the photosensitizer Ce6, exploiting the characteristic of tumor cells to recruit and lipolyze adipocytes for energy.

View Article and Find Full Text PDF

Objective: The effects of sex hormones remain largely unexplored in pheochromocytomas and paragangliomas (PPGLs) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Methods: We evaluated the effects of estradiol, progesterone, Dehydroepiandrosterone sulfate (DHEAS), and testosterone on human patient-derived PPGL/GEP-NET primary culture cell viability (n = 38/n = 12), performed next-generation sequencing and immunohistochemical hormone receptor analysis in patient-derived PPGL tumor tissues (n = 36).

Results: In PPGLs, estradiol and progesterone (1 µm) demonstrated overall significant antitumor effects with the strongest efficacy in PPGLs with NF1 (cluster 2) pathogenic variants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!